Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-26-019473
Filing Date
2026-04-29
Accepted
2026-04-29 08:00:29
Documents
17
Period of Report
2026-04-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A formdef14a.htm   iXBRL DEF 14A 610390
2 GRAPHIC formdef14a_001.jpg GRAPHIC 17421
3 GRAPHIC proxy_001.jpg GRAPHIC 331195
4 GRAPHIC proxy_002.jpg GRAPHIC 341414
  Complete submission text file 0001493152-26-019473.txt   2726114

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE gnlx-20251231.xsd EX-101.SCH 3413
6 XBRL DEFINITION FILE gnlx-20251231_def.xml EX-101.DEF 3363
7 XBRL LABEL FILE gnlx-20251231_lab.xml EX-101.LAB 53108
8 XBRL PRESENTATION FILE gnlx-20251231_pre.xml EX-101.PRE 41976
20 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 2781
Mailing Address 2625 TOWNSGATE ROAD, SUITE 230 WESTLAKE VILLAGE CA 91361
Business Address 2625 TOWNSGATE ROAD, SUITE 230 WESTLAKE VILLAGE CA 91361 805-267-9889
GENELUX Corp (Filer) CIK: 0001231457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41599 | Film No.: 26910613
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)